pharmacanada - bladder cancer & early cancer detection
TRANSCRIPT
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 1/12
www.earlycancerdetect.com
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 2/12
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 3/12
World Health Organization reported an estimated 386,300 new cases and150,200 deaths from bladder cancer which occurred since 2008 worldwide andmajority of it occurs in males.
Bladder cancer is an uncontrolled abnormal growth and multiplication of cells inthe urinary bladder which have broken free from the normal control mechanismsof the body. It has the ability to spread to other parts of the body including thelungs, bones, and liver.
is the most common type which is usually associated withcigarette smoking having 50% incidence found in men and 30% in women.
of the bladder comprises about 2% and is associated with
prolonged inflammation and irritation. And the third type is calledcell carcinoma which comprises 1%-2% of bladder cancers and is associated withprolonged infection, inflammation, and irritation such as that associated withlongstanding stones in the bladder.
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 4/12
According to research the longer and heavier the exposure tocigarette smoking, the greater the chance of developing bladdercancer. Most toxic chemicals in cigarette smoke are knowncarcinogens and travel in the bloodstream after being absorbedfrom the lungs and get filtered into the urine by the kidneys. Itcomes in contact with cells in the inner lining of the urinarysystem, including the bladder, and cause changes that developinto cancer cells.
Men are more prone to developing cancer and at the highest risk
due to a higher incidence of smoking and exposure to toxicchemicals with jobs including dye, rubber, aluminum, andleather workers, truck drivers, and pesticide applicators.
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 5/12
Painless hematuria (blood in the urine) that occurs in episodes
Blood in the urine that has pain due to the blockage of urine by
formation of blood clots;
Patients may have the desire to urinate in small amounts and in
short frequency,
Inability to hold the urine for any length of time after the initialdesire to void, or burning sensation while passing urine (dysuria);
In advance stages, there may be bladder distention due to an
obstruction of a tumor in the bladder neck. Flank pains may also be
experienced due to obstruction of urine flow from the kidney to the
bladder by a growing tumor mass in the bladder. Also, bone or joint
pains, hemoptysis (coughing of blood) may be noted due to spread
of cancer cells to the bones and/or lungs.
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 6/12
For a low-risk superficial bladder cancer, the chance of
recurrence is about 15% in one year and 32% in five years
after the initial diagnosis.
For High-risk superficial tumors, multiple and large
tumors are at increased risk for recurrence andprogression. These tumors have a recurrence rate of 61%-
78% at one and five years respectively. They are also much
likely to invade into the deeper layers with progression
rates of 17%-45% at one and five years. Currently, bladder cancer is a topic of intense scientific
research.
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 7/12
made possible in the Philippines byPharmaCanada and PMILabs in partnership with
St Dominic Medical Center.
screening test
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 8/12
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 9/12
The ClearCyte™ system is an automated image
cytometer that enables analysis of DNA content in
slide-based cytology specimens. The system is veryuser friendly, easy to maintain and offers a high
output capacity due to fully automated scanning
process. ClearCyte™ is an in-vitro medical device
with Health Canada and European CE Markapprovals. It has been designed under ISO and FDA
development requirements.
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 10/12
Precision measurements with precision DNA
staining protocol
Intelligent sorting capabilities – excellentautomated discrimination of isolated, measurable
cell nuclei
Walk-away automation (up to 50 slides per batch)
High output (up to 2000 objects per minute) Interactive and flexible data review and reporting
8/3/2019 PharmaCanada - Bladder Cancer & Early Cancer Detection
http://slidepdf.com/reader/full/pharmacanada-bladder-cancer-early-cancer-detection 11/12
Early Cancer Detection (ECD) test
Call : (632) 553-4276, (632) 553-4205
Visit: PharmaCanada Inc.
Penthouse 4, VGP Center, 6772Ayala Ave., Makati City Phils.
E-mail: [email protected]
Website: www.earlycancerdetect.com
Test available at select medical and diagnostic centres.Visit http://earlycancerdetect.com/main/?page_id=646 formore information.